• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOFIRE DIAGNOSTICS, LLC BIOFIRE® FILMARRAY® GASTROINTESTINAL (GI) PANEL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOFIRE DIAGNOSTICS, LLC BIOFIRE® FILMARRAY® GASTROINTESTINAL (GI) PANEL Back to Search Results
Model Number RFIT-ASY-0116
Device Problem False Positive Result (1227)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 02/23/2024
Event Type  malfunction  
Manufacturer Narrative
Investigation: a potential false positive v.Cholerae result on the biofire gi panel was reported after testing a patient stool sample in cary blair transport media on (b)(6) 2024.A repeat test of the sample on the biofire gi panel on the same day did not detect v.Cholerae.The patient was not affected due to the biofire gi panel result as the result was not reported to the physician.No serious injury or death occurred.Conclusion: the investigation determined that the most likely cause of the discrepant v.Cholerae] result was the presence of non-viable organism/nucleic acid in the cary blair transport media.While cary blair medium vials are autoclaved and routinely quality controlled for sterility, non-viable organisms or nucleic acids can remain in the transport medium after the sterilization process.The presence of non-viable organisms and nucleic acid does not compromise the intended use of transport medium, transportation and preservation of clinical stool and rectal specimens; however, the biofire gi panel does not distinguish between nucleic acid from viable or non-viable organisms.The "laboratory precaution" and "limitation" sections of the filmarray gi reagent instruction booklet (https://www.Online-ifu.Com/iti0030) outlines the potential for false positive detections during molecular testing with sterile cary blair transport medium containing detectable levels of non-viable organisms and/or nucleic acid.Importantly, results from the biofire gi panel are intended to be correlated with the clinical history, epidemiological data, and other data available to the clinician evaluating the patient.Detection of organism targets does not imply that the corresponding organisms are infectious or are the causative agents for clinical symptoms.Clinical performance: according to table 11.Biofire gi clinical performance summary of the filmarray gi reagent instruction booklet, the performance claim for the v.Cholerae assay compared to stool culture with standard manual/automated microbiological/biochemical identification showed a specificity of 99.9% (95% ci 99.6-100%).V.Cholerae was detected in the single false positive specimen using bi-directional sequence analysis.To supplement the prospective data, an evaluation of contrived specimens was performed.According to table 18.Biofire gi panel performance using contrived specimens of the filmarray gi reagent instruction booklet, the performance claim for v.Cholerae showed a positive percent agreement (ppa) of 84.6% (95% ci 73.5-92.4%) and a negative percent agreement (npa) of 100% (95% ci 96.7-100%).Ten of the contrived specimens were spiked with an isolate which was found to have a highly divergent toxr gene that was not present in the ncbi database and non-reactive with the biofire gi panel v.Cholerae assay.The biofire gi panel vibrio assay was positive for nine of these specimens.
 
Event Description
Summary: (b)(6) hospital reported a potential false positive vibrio cholerae result on the biofire® filmarray® gastrointestinal (gi) panel after testing a patient stool sample in cary blair transport media.The patient was not affected due to the biofire gi panel result as the result was not reported to the physician.The investigation determined that the most likely cause of the discrepant v.Cholerae result was the presence of non-viable organism/nucleic acid in the cary blair transport media.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BIOFIRE® FILMARRAY® GASTROINTESTINAL (GI) PANEL
Type of Device
BIOFIRE® FILMARRAY® GASTROINTESTINAL (GI) PANEL
Manufacturer (Section D)
BIOFIRE DIAGNOSTICS, LLC
515 colorow dr
salt lake city UT 84108
Manufacturer (Section G)
BIOFIRE DIAGNOSTICS, LLC
515 colorow dr
salt lake city UT 84108
Manufacturer Contact
515 colorow dr
salt lake city, UT 84108
8017366354
MDR Report Key19001004
MDR Text Key339151785
Report Number3002773840-2024-00295
Device Sequence Number1
Product Code PCH
UDI-Device Identifier00815381020109
UDI-Public00815381020109
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K230404
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 03/28/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberRFIT-ASY-0116
Device Catalogue NumberRFIT-ASY-0116
Device Lot Number2547423
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 02/28/2024
Initial Date FDA Received03/28/2024
Was Device Evaluated by Manufacturer? No
Date Device Manufactured10/18/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Age87 YR
Patient SexMale
-
-